Centrifuge to enable scalability launched through Thermo Fisher partnership

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/kritchanut)
(Image: Getty/kritchanut)

Related tags: Thermo fisher, Manufacturing, Gene therapy, Cell therapy, Cell therapy manufacturing

Thermo Fisher and Scinogy partner to improve scalability and cost-effectiveness of cell and gene therapy manufacture through the addition of the former’s centrifuge.

Scinogy, an automated manufacturing systems provider for cell therapies, and Thermo Fisher Scientific will work to develop and commercialize reagent systems to improve the scalability of cell and gene therapy manufacturing.

With Scinogy, Thermo Fisher will provide closed, modular, and automated systems for the development and manufacturing of cell and gene therapy – to be used as an alternative method to the manual processes used in development and clinical trial supply.

Per the partnership agreement, Thermo Fisher will launch its counterflow centrifuge used for closed cell processing in cell and gene therapy manufacturing. According to the company, the Gibco CTS Rotea Counterflow Centrifugation System, is a highly reproducible system for separation, washing, and concentration of autologous and small-scale allogeneic cell therapy samples.

According to Bryan Poltilove, general manager of cell therapy for Thermo Fisher Scientific, this fulfills the market’s need for closed, modular, automated systems, which enable scalable and cost-effective development and manufacturing.

The Rotea can continuously process up to 20L of starting volume to then deliver a concentrate as small as 5ml that contains up to 200m cells per millimeter.

Politilove explained, “This centrifuge provides rapid processing of cells across a wide range of volumes with high levels of precision. By enabling closed manufacturing of cell therapies, it can reduce costs and improve scalability for commercial manufacturing.”

Financial details of the agreement have not been disclosed.

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more